BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced that an article titled “Non-hallucinogenic LSD derivative reduces depression symptoms in preclinical studies,” based on BetterLife’s lead candidate BETR-001 (2-bromo-LSD) was published by Drug Discovery & Development on March 22, 2023.
The emerging biotech company said the Drug Discovery & Development article describes and adds further comments to the positive data and extensive pharmacological characterization of BETR-001 which were published recently in the peer-reviewed journal Cell Reports.
“As highlighted in this article, BetterLife’s proprietary BETR-001 (patent pending) has significant therapeutic potential in neuro-psychiatric disorders (as well as) an improved safety profile compared with LSD,” BetterLife Pharma CEO Ahmad Doroudian said in a statement.
READ: BetterLife Pharma closes $1.5M private placement
“We are progressing with our BETR-001 IND-enabling studies and project to begin BETR-001 human clinical trials following the completion of the IND-enabling studies,” Doroudian added.
BetterLife noted the studies were performed by BetterLife in collaboration with several leading scientists in this field: Dr Adam L. Halberstadt (University of California San Diego, US), Dr Argel Aguilar-Valles (Carleton University, Canada), and Dr John D. McCorvy (Medical College of Wisconsin, US).
BetterLife Pharma is an emerging biotechnology company focused primarily on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuropsychiatric and neurological disorders.
Contact Sean at sean@proactiveinvestors.com